Targeting chemokines for acute lymphoblastic leukemia therapy

22Citations
Citations of this article
49Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Acute lymphoblastic leukemia (ALL) is a hematological malignancy characterized by the malignant clonal expansion of lymphoid hematopoietic precursors. It is regulated by various signaling molecules such as cytokines and adhesion molecules in its microenvironment. Chemokines are chemotactic cytokines that regulate migration, positioning and interactions of cells. Many chemokine axes such as CXCL12/CXCR4 and CCL25/CCR9 have been proved to play important roles in leukemia microenvironment and further affect ALL outcomes. In this review, we summarize the chemokines that are involved in ALL progression and elaborate on their roles and mechanisms in leukemia cell proliferation, infiltration, drug resistance and disease relapse. We also discuss the potential of targeting chemokine axes for ALL treatments, since many related inhibitors have shown promising efficacy in preclinical trials, and some of them have entered clinical trials.

Cite

CITATION STYLE

APA

Hong, Z., Wei, Z., Xie, T., Fu, L., Sun, J., Zhou, F., … Shao, L. (2021, December 1). Targeting chemokines for acute lymphoblastic leukemia therapy. Journal of Hematology and Oncology. BioMed Central Ltd. https://doi.org/10.1186/s13045-021-01060-y

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free